Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide

J B Bartlett; A Tozer; D Stirling; J B Zeldis

doi:10.1038/sj.bjc.6602774

Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide

Br J Cancer. 2005 Sep 19;93(6):613-9. doi: 10.1038/sj.bjc.6602774.

Authors

J B Bartlett¹, A Tozer, D Stirling, J B Zeldis

Affiliation

¹ Celgene Corporation, 86 Morris Avenue, Summit, NJ 07901, USA. bbartlett@celgene.com

Abstract

Thalidomide is effective in the treatment of multiple myeloma. The immunomodulatory drug and thalidomide analogue lenalidomide is currently in late stage clinical development for MDS and multiple myeloma. This minireview highlights the course of initial and ongoing lenalidomide clinical development in oncology with reference to earlier thalidomide studies.

Publication types

Review

MeSH terms

Clinical Trials as Topic
Humans
Immunologic Factors
Immunosuppressive Agents / therapeutic use*
Lenalidomide
Multiple Myeloma / drug therapy*
Myelodysplastic Syndromes / drug therapy*
Myelodysplastic Syndromes / immunology
Thalidomide / analogs & derivatives*
Thalidomide / therapeutic use

Substances

Immunologic Factors
Immunosuppressive Agents
Thalidomide
Lenalidomide